By Steve Goldstein & Jaimy Lee
The reported tie-up talks are moving stocks. Analysts are puzzled.
"Odd" is the word that analysts are using to describe a potential Bristol-Myers Squibb tie-up with AstraZeneca.
AstraZeneca and Bristol Myers Squibb are reportedly in talks to merge and create one of the world's largest drugmakers - and a cancer-drug powerhouse.
AstraZeneca shares (AZN) (UK:AZN) tumbled about 8% on Monday morning, while Bristol Myers Squibb (BMY) was down about 1%. The Financial Times first reported the talks on Sunday, characterized as early stage.
